SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

TENX.US.STK (TENX.US.STK) News

Follow TENX.US.STK (TENX.US.STK) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol TENX.US.STK Asset market Sector Markets 90 days 1 Updated Jul 28, 2026, 12:12 PM UTC Open live news feed
H TENX Canaccord initiated coverage of Tenax Therapeutics with a Buy rating and $35 price target. Tenax is a clinical-stage biopharma developi TENX Canaccord initiated coverage of Tenax Therapeutics with a Buy rating and $35 price target. Tenax is a clinical-stage biopharma developing TNX-103 for the treatment of pulmonary hypertension associated with heart fai GEOPOLITICS | Jul 28, 2026, 12:12 PM UTC